Genetics and cytogenetics of Waldenstrom's macroglobulinemia

Seminars in Oncology

Volumn 30, Issue 2, 2003, Pages 142-145

  Schop, Roelandt F J ^a   Fonseca, Rafael ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN; PARAPROTEIN;

ANEUPLOIDY; B LYMPHOCYTE; CHROMOSOME 6; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION; CLONE; CYTOGENETICS; FAMILIAL DISEASE; GENE DELETION; GENETIC ANALYSIS; GENETIC STABILITY; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; WALDENSTROEM MACROGLOBULINEMIA;

EID: 0242501569     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2003.50075     Document Type: Review

References (40)

1. Dimopoulos MA, Panayiotidis P, Moulopoulos LA, et al: Waldenstrom's macroglobulinemia: Clinical features, complications, and management. J Clin Oncol 18:214-226, 2000
2. Gertz MA, Fonseca R, Rajkumar SV: Waldenstrom's macroglobulinemia. Oncologist 5:63-67, 2000
3. Harris NL, Jaffe ES, Stein H, et al: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994
4. Offit K, Parsa NZ, Filippa D, et al: t(9;14)(p13;q32) denotes a subset of low-grade non-Hodgkin's lymphoma with plasmacytoid differentiation. Blood 80:2594-2599, 1992
5. Morrison AM, Jager U, Chott A, et al: Deregulated PAX-5 transcription from a translocated IgH promoter in marginal zone lymphoma. Blood 92:3865-3878, 1998
6. Singh M, Birshtein BK: NF-HB (BSAP) is a repressor of the murine immunoglobulin heavy-chain 3′ alpha enhancer at early stages of B-cell differentiation. Mol Cell Biol 13:3611-3622, 1993
7. Neurath MF, Strober W, Wakatsuki Y: The murine Ig 3′ alpha enhancer is a target site with repressor function for the B cell lineage-specific transcription factor BSAP (NF-HB, S alpha-BP). J Immunol 153:730-742, 1994
8. Neurath MF, Max EE, Strober W: Pax5 (BSAP) regulates the murine immunoglobulin 3′ alpha enhancer by suppressing binding of NF-alpha P, a protein that controls heavy chain transcription. Proc Natl Acad Sci USA 92:5336-5340, 1995
9. Max EE, Wakatsuki Y, Neurath MF, et al: The role of BSAP in immunoglobulin isotype switching and B-cell proliferation. Curr Topics Microbiol Immunol 194:449-458, 1995
10. Neurath MF, Stuber ER, Strober W: BSAP: A key regulator of B-cell development and differentiation. Immunol Today 16:564-569, 1995
11. Chong YY, Lau LC, Lui WO, et al: A case of t(8;14) with total and partial trisomy 3 in Waldenstrom macroglobulinemia. Cancer Genet Cytogenet 103:65-67, 1998
12. San Roman C, Ferro T, Guzman M, et al: Clonal abnormalities in patients with Waldenstrom's macroglobulinemia with special reference to a Burkitt-type t(8;14). Cancer Genet Cytogenet 18:155-158, 1985
13. Nishida K, Taniwaki M, Misawa S, et al: Nonrandom rearrangement of chromosome 14 at band q32.33 in human lymphoid malignancies with mature B-cell phenotype. Cancer Res 49:1275-1281, 1989
14. Calasanz MJ, Cigudosa JC, Odero MD, et al: Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: primary breakpoints and clinical correlations. Genes Chromosomes Cancer 18:84-93, 1997
15. Schop R, Kuehl W, Van Wier S, et al: Waldenström's macroglobulinemia neoplastic cells lack IgH translocations but have frequent 6q deletions. Blood 100:2996-3001, 2002
16. Mansoor A, Medeiros LJ, Weber DM, et al: Cytogenetic findings in lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia. Chromosomal abnormalities are associated with the polymorphous subtype and an aggressive clinical course. Am J Clin Pathol 116:543-549, 2001
17. Louviaux I, Michaux L, Hagemeijer A, et al: Cytogenetic abnormalities in Waldenstrom's disease (WD): A single centre study of 45 cases. Blood 92:184b, 1998 (suppl 1, abstr 3776)
18. Jalal SM, Law ME, Stamberg J, et al: Detection of diagnostically critical, often hidden, anomalies in complex karyotypes of haematological disorders using multicolour fluorescence in situ hybridization. Br J Haematol 112:975-980, 2001
19. Schrock E, Veldman T, Padilla-Nash H, et al: Spectral karyotyping refines cytogenetic diagnostics of constitutional chromosomal abnormalities. Hum Genet 101:255-262, 1997
20. Sahota SS, Garand R, Bataille R, et al: VH gene analysis of clonally related IgM and IgG from human lymphoplasmacytoid B-cell tumors with chronic lymphocytic leukemia features and high serum monoclonal IgG. Blood 91:238-243, 1998
21. Ciric B, VanKeulen V, Rodriguez M, et al: Clonal evolution in Waldenstrom macroglobulinemia highlights functional role of B-cell receptor. Blood 97:321-323, 2001
22. Bergsagel PL, Chesi M, Nardini E, et al: Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc Natl Acad Sci USA 93:13931-13936, 1996
23. Gabrea A, Bergsagel PL, Chesi M, et al: Insertion of excised IgH switch sequences causes overexpression of cyclin D1 in a myeloma tumor cell. Mol Cell 3:119-123, 1993
24. Fonseca R, Oken M, Harrington D, et al: Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q-arm or monosomy. Leukemia 15:981-986, 2001
25. Avet-Loiseau H, Daviet A, Saunier S, et al: Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13. Br J Haematol 111:1116-1117, 2001
26. Schop R, Jalal S, Van Wier S, et al: Deletions of 17p13.1 and 13q14 are uncommon in Waldenstrom macroglobulinemia clonal cells and mostly seen at the time of disease progression. Cancer Genet Cytogenet 132:55-60, 2002
27. Hirase N, Miyamura T, Ishikura H, et al: Primary macroglobulinemia with t(11;18) (q21;q21) [Japanese]. Rinsho Ketsueki 37:340-345, 1996
28. Hirase N, Yufu Y, Abe Y, et al: Primary macroglobulinemia with t(11;18)(q21;q21). Cancer Genet Cytogenet 117:113-117, 2000
29. Dierlamm J, Wlodarska I, Michaux L, et al: Genetic abnormalities in marginal zone B-cell lymphoma. Hematol Oncol 18:1-13, 2000
30. Remstein ED, James CD, Kurtin PJ: Incidence and sub-type specificity of API2-MALT1 fusion translocations in extranodal, nodal, and splenic marginal zone lymphomas. Am J Pathol 156:1183-1188, 2000
31. Bunn PA Jr, Krasnow S, Makuch RW, et al: Flow cytometric analysis of DNA content of bone marrow cells in patients with plasma cell myeloma: Clinical implications. Blood 59:528-535, 1982
32. Wong KF, So CC: Waldenstrom macroglobulinemia with karyotypic aberrations involving both homologous 6q. Cancer Genet Cytogenet 124:137-139, 2001
33. Patau K: Chromosomal abnormalities in Waldenstrom's macroglobulinemia. Lancet 2:600, 1961
34. Han T, Sadamori N, Takeuchi J, et al: Clonal chromosome abnormalities in patients with Waldenstrom's and CLL-associated macroglobulinemia: Significance of trisomy 12. Blood 62:525-531, 1983
35. Broustet A, Veyret V, Moretti G: Chromosomal and cytochemical aspects of Waldenstrom's disease [French]. Ann Biol Clin 26:17-46, 1968
36. Bottura C, Ferrari I, Veiga A: Chromosomal abnormalities in Waldenstrom's macroglobulinemia. Lancet 1:1170, 1961
37. Parsa NZ, Gaidano G, Mukherjee AB, et al: Cytogenetic and molecular analysis of 6q deletions in Burkitt's lymphoma cell lines. Genes Chromosomes Cancer 9:13-18, 1994
38. Offit K, Parsa NZ, Gaidano G, et al: 6q deletions define distinct clinico-pathologic subsets of non-Hodgkin's lymphoma. Blood 82:2157-2162, 1993
39. Gaidano G, Hauptschein RS, Parsa NZ, et al: Deletions involving two distinct regions of 6q in B-cell non-Hodgkin lymphoma. Blood 80:1781-1787, 1992
40. Dohner H, Stilgenbauer S, Benner A, et al: Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910-1916, 2000